204 related articles for article (PubMed ID: 15863405)
1. Counting the true cost of antiplatelet therapy for stroke prevention.
Morton JA; Newton J; Gray CS
Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
[No Abstract] [Full Text] [Related]
2. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Rothlisberger JM; Ovbiagele B
J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
[TBL] [Abstract][Full Text] [Related]
3. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Redman AR; Ryan GJ
Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
5. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
7. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
8. Aggrenox: an aspirin and extended-release dipyridamole combination.
Wong NN
Heart Dis; 2001; 3(5):340-6. PubMed ID: 11975816
[TBL] [Abstract][Full Text] [Related]
9. CAPRIE trial.
Barer D
Lancet; 1997 Feb; 349(9048):355-6. PubMed ID: 9024397
[No Abstract] [Full Text] [Related]
10. Aggrenox: a combination of antiplatelet drugs for stroke prevention.
Med Lett Drugs Ther; 2000 Feb; 42(1071):11-2. PubMed ID: 10725967
[No Abstract] [Full Text] [Related]
11. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
[TBL] [Abstract][Full Text] [Related]
12. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Warlow C
Stroke; 2002 Aug; 33(8):2137-8. PubMed ID: 12154276
[No Abstract] [Full Text] [Related]
13. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Hankey GJ
Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
[TBL] [Abstract][Full Text] [Related]
14. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
[No Abstract] [Full Text] [Related]
15. Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Eriksson P
Am J Med; 2005 Feb; 118(2):199-200; author reply 200. PubMed ID: 15694910
[No Abstract] [Full Text] [Related]
16. Newer antiplatelet therapies in stroke prevention.
Davis SM; Donnan GA
Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic drugs for secondary stroke prophylaxis--a comment.
Hansen DB
Pharmacotherapy; 2001 Aug; 21(8):1020; author reply 1021-2. PubMed ID: 11718493
[No Abstract] [Full Text] [Related]
18. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Simmons BB; Yeo A; Fung K; ;
Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
Lenz T; Wilson A
Clin Pharmacokinet; 2003; 42(10):909-20. PubMed ID: 12885264
[TBL] [Abstract][Full Text] [Related]
20. Update on the use of antiplatelet agents in secondary stroke prevention.
Jamieson DG
J Natl Med Assoc; 2007 Mar; 99(3):306. PubMed ID: 17393957
[No Abstract] [Full Text] [Related]
[Next] [New Search]
